Skip to main content Skip to navigation

A to Z of MS Beta interferon 1a

Product name

Rebif

Rebif (beta interferon 1a) is one of the disease modifying drugs licensed for relapsing/remitting MS and some people with secondary progressive MS. These drugs are often referred to collectively as the beta interferons. Studies have shown that on average Rebif reduces the relapse rate in people with relapsing/remitting MS by about a third and also reduces the severity of those relapses that do occur.

How beta interferon works

Interferons are proteins that occur naturally in the immune system. It is thought that beta interferon acts by reducing both inflammation and the immune response that is attacking the body's own myelin.

How is Rebif given?

Rebif is injected under the skin three times a week.

Side effects and contraindications

Flu like symptoms following injections. These tend to reduce over time and are usually no longer a problem after three months on treatment. Injection site reactions such as redness, swelling, and occasionally itching or some pain at the site. These also reduce over time.

Storage

A new formulation of Rebif was introduced in spring 2008. Rebif must now be stored in the fridge (between 2 and 8 degrees) and injected as soon as possible after removal from refrigeration. Storage at room temperature is not recommended.

Reference

PRISMS Study Group.
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.
Lancet 1998;352:1498-1504.

Return to index